Cited 8 times in
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범경 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 윤기태 | - |
dc.contributor.author | 이정일 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2017-10-26T08:13:12Z | - |
dc.date.available | 2017-10-26T08:13:12Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/153153 | - |
dc.description.abstract | BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). METHODS: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks. RESULTS: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred. CONCLUSION: In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenine/analogs & derivatives* | - |
dc.subject.MESH | Adenine/therapeutic use | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Drug Resistance, Viral | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepatitis B e Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organophosphonates/therapeutic use* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Tenofovir/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study) | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Moon Young Kim | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Young Suk Kim | - |
dc.contributor.googleauthor | Ki Tae Yoon | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.identifier.doi | 10.3350/cmh.2016.0037 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02544 | - |
dc.contributor.localId | A03122 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00487 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.relation.journalsince | 2012~ | - |
dc.identifier.pmid | 27880997 | - |
dc.relation.journalbefore | ~2012 Korean Journal of Hepatology (대한간학회지) | - |
dc.subject.keyword | Adefovir | - |
dc.subject.keyword | Chronic hepatitis B | - |
dc.subject.keyword | Complete virological response | - |
dc.subject.keyword | Suboptimal response | - |
dc.subject.keyword | Tenofovir | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Yoon, Ki Tae | - |
dc.contributor.alternativeName | Lee, Jung Il | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Yoon, Ki Tae | - |
dc.contributor.affiliatedAuthor | Lee, Jung Il | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.citation.volume | 22 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 443 | - |
dc.citation.endPage | 449 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.22(4) : 443-449, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 41150 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.